Therapeutic effect of psilocybin in addiction: A systematic review
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Background: Psychedelic-assisted therapy [e.g., with lysergic acid diethylamide (LSD)] has shown promising results as treatment for substance use disorders (SUDs). Previous systematic reviews assessing the efficacy of psilocybin in SUDs only included clinical trials conducted in the last 25 years, but they may have missed clinical trials assessing the efficacy of psilocybin that were conducted before the 1980s, given much research has been done with psychedelics in the mid-20th century. In this systematic review, we specifically assessed the efficacy of psilocybin in patients with a SUD or non-substance-related disorder with no publication date restrictions in our search strategy. Methods: A systematic literature search was performed according to Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines from the earliest published manuscript up to September 2, 2022, in seven electronic databases, including clinical trials in patients with a SUD or non-substance-related disorder evaluating the efficacy of psilocybin. Results: A total of four studies (six articles, of which two articles were long-term follow-up results from the same trial) were included in this systematic review. Psilocybin-assisted therapy was administered to n = 151 patients in a dose ranging from 6 to 40 mg. Three studies focused on alcohol use disorder, and one study on tobacco use disorder. In a pilot study (n = 10), the percentage of heavy drinking days decreased significantly between baseline and weeks 5–12 (mean difference of 26.0, 95% CI = 8.7–43.2, p = 0.008). In another single-arm study (n = 31), 32% (10/31) became completely abstinent from alcohol (mean duration of follow-up 6 years). In a double-blind, placebo-controlled randomized controlled trial (RCT, n = 95), the percentage of heavy drinking days during the 32-week double-blind period was significantly lower for psilocybin compared to placebo (mean difference of 13.9, 95% CI = 3.0–24.7, p = 0.01). In a pilot study (n = 15), the 7-day point prevalence of smoking abstinence at 26 weeks was 80% (12/15), and at 52 weeks 67% (10/15). Conclusion: Only one RCT and three small clinical trials were identified assessing the efficacy of psilocybin combined with some form of psychotherapy in patients with alcohol and tobacco use disorder. All four clinical trials indicated a beneficial effect of psilocybin-assisted therapy on SUD symptoms. Larger RCTs in patients with SUDs need to evaluate whether psilocybin-assisted therapy is effective in patients with SUD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We enrolled 27% of those pre-screened, which is comparable with similar studies of PAT for addiction [15,25,51] and treatment-resistant depression [52,53].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [51]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Prior studies of PAT for substance use disorders have found similarly positive efficacy signals [51].”
From Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study. (2025) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01626-4 · Cited by 13,874
Degenhardt, L., Charlson, F., Ferrari, A., Santomauro, D., Erskine, H., Mantilla-Herrara, A., Whiteford, H., Leung, J., Naghavi, M., Griswold, M., et al. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30337-7 · Cited by 1,572
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 8×
“(29, 30) was included assessing the efficacy of psilocybin-assisted therapy in n = 15 patients who met the following criteria: smoking ≥10 cigarettes per day, being healthy as determined by medical interview, multiple unsuccessful past quit attempts, and the desire to quit smoking.”
BackgroundInfluentialBogenschutz, M. P., Ross, S., Bhatt, S., Baron, T., Forcehimes, A. A., Laska, E., Mennenga, S. E., O’Donnell, K., Owens, L. T., Podrebarac, S., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2096 · Cited by 711
Long-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583
Cannabis use and cannabis use disorder
Connor, J. P., Stjepanović, D., Le Foll, B., Hoch, E., Budney, A. J., & Hall, W. D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00247-4 · Cited by 552 · cited 1×
“It is less clear why no clinical trials in cannabis use disorder are currently conducted as it is the most common drug use disorder worldwide, especially among youth (42).”
BackgroundGriffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117731279 · Cited by 520 · cited 1×
“, the degree to which a patient has a mysticaltype experience during the psilocybin session seems an important mediator for the enduring effect of the psilocybin) (25, 37).”
BackgroundNew findings on biological factors predicting addiction relapse vulnerability
Sinha, R. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0224-0 · Cited by 401 · cited 4×
“The assessment of each included study in the review followed the following six steps: (1) to specify the research question through consideration of a target trial; (2) to specify the outcome and result being assessed; (3) for the specified result, to examine how the confounders and co-interventions were addressed; (4)…”
BackgroundMethodInfluentialAndersen, K. A. A., Carhart‐Harris, R., Nutt, D. J., & Erritzoe, D. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13249 · Cited by 347
Blinding and expectancy confounds in psychedelic randomized controlled trials
Muthukumaraswamy, S. D., Forsyth, A., & Lumley, T. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933434 · Cited by 324 · cited 2×
“Still, a risk is that external validity is relatively low and that diminished effects will be observed with psilocybin in a therapeutic setting (33).”
BackgroundNeuroscience of Addiction: Relevance to Prevention and Treatment
Volkow, N. D., & Boyle, M. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17101174 · Cited by 322
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306
The use of the psychological flexibility model to support psychedelic assisted therapy
Watts, R., & Luoma, J. B. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.12.004 · Cited by 269
de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.724606 · Cited by 269 · cited 2×
“Both LSD and psilocybin primarily act via stimulation of the 5-HT2A-receptors, but LSD exhibits additional affinity for dopaminergic and α-adrenergic receptors (34).”
BackgroundHolze, F., Ley, L., Müller, F., Becker, A. M., Straumann, I., Vizeli, P., Kuehne, S. S., Roder, M. A., Duthaler, U., Kolaczynska, K. E., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01297-2 · Cited by 226 · cited 3×
“The onset of effects is significantly earlier, and the duration is substantially longer in LSD compared to psilocybin (35).”
BackgroundPharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
van Elk, M., & Yaden, D. B. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104793 · Cited by 221
The promises and perils of psychedelic pharmacology for psychiatry
McClure-Begley, T. D., & Roth, B. L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00421-7 · Cited by 194
Self-blinding citizen science to explore psychedelic microdosing
Szigeti, B., Kartner, L., Blemings, A., Rosas, F., Feilding, A., Nutt, D. J., Carhart-Harris, R. L., & Erritzoe, D. (2021) · eLife · doi:10.7554/elife.62878 · Cited by 192
Retrospective and Prospective Reports of Precipitants to Relapse in Pathological Gambling.
Hodgins, D. C., & el-Guebaly, N. (2004) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.72.1.72 · Cited by 190
Castaldelli-Maia, J. M., & Bhugra, D. (2022) · International Review of Psychiatry · doi:10.1080/09540261.2022.2040450 · Cited by 187
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials
Fuentes, J. J., Fonseca, F., Elices, M., Farré, M., & Torrens, M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00943 · Cited by 177
Self-citationGrabski, M., McAndrew, A., Lawn, W., Marsh, B., Raymen, L., Stevens, T., Hardy, L., Warren, F., Bloomfield, M., Borissova, A., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21030277 · Cited by 175
Schimmers, N., Breeksema, J. J., Smith-Apeldoorn, S. Y., Veraart, J., van den Brink, W., & Schoevers, R. A. (2022) · Psychopharmacology · doi:10.1007/s00213-021-06027-y · Cited by 162
Kelmendi, B., Kaye, A. P., Pittenger, C., & Kwan, A. C. (2022) · Current Biology · doi:10.1016/j.cub.2021.12.009 · Cited by 150
Residential Psychedelic (LSD) Therapy for the Narcotic Addict: A Controlled Study
Savage, C. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750360040005 · Cited by 148 · cited 1×
“Savage and McCabe (16) also found a beneficial effect of LSD on heroin use disorder in n = 78 inmates of correctional institutions (16).”
BackgroundPositive expectations predict improved mental-health outcomes linked to psychedelic microdosing
Kaertner, L. S., Steinborn, M. B., Kettner, H., Spriggs, M. J., Roseman, L., Buchborn, T., Balaet, M., Timmermann, C., Erritzoe, D., & Carhart-Harris, R. L. (2021) · Scientific Reports · doi:10.1038/s41598-021-81446-7 · Cited by 145 · cited 1×
“Pretreatment-positive expectations about psychedelic microdosing predicted improvements in psychiatric symptoms (38).”
BackgroundDARK Classics in Chemical Neuroscience: Psilocybin
Geiger, H. A., Wurst, M. G., & Daniels, R. N. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00186 · Cited by 141
Garcia-Romeu, A., Barrett, F. S., Carbonaro, T. M., Johnson, M. W., & Griffiths, R. R. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121991822 · Cited by 96 · cited 1×
“In addition, all the included studies in this systematic review adjusted psilocybin dose to body weight, (25–30) although there is no clear benefit for this adjustment and fixed dosing is more practical in clinical trials (35, 36).”
BackgroundDark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)
Nichols, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00043 · Cited by 90
Why was early therapeutic research on psychedelic drugs abandoned?
Hall, W. (2022) · Psychological Medicine · doi:10.1017/s0033291721004207 · Cited by 86
Wilkinson, S. T., Farmer, C., Ballard, E. D., Mathew, S. J., Grunebaum, M. F., Murrough, J. W., Šóš, P., Wang, G., Gueorguieva, R. V., & Zarate, C. A. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0317-8 · Cited by 79
Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies
Calleja‐Conde, J., Morales-Garcia, J. A., Echeverry‐Alzate, V., Bühler, K., Giné, E., & López‐Moreno, J. A. (2022) · Addiction Biology · doi:10.1111/adb.13229 · Cited by 63
Debating the Controlled Substances Act
Spillane, J. F. (2004) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.04.011 · Cited by 49
CE: Psychedelic-Assisted Therapy
Penn, A., Dorsen, C. G., Hope, S., & Rosa, W. E. (2021) · AJN American Journal of Nursing · doi:10.1097/01.naj.0000753464.35523.29 · Cited by 45
Theoretical Aspects of L.S.D. Therapy
Buckman, J. (1967) · International Journal of Social Psychiatry · doi:10.1177/002076406701300205 · Cited by 13
Treatment of alcoholism with psychotomimetic drugs. A follow-up study.
Rydzyński, Z., & Gruszczyński, W. (1978) · PubMed · Cited by 9
Prelminary report on the experience with psychosomimetic drugs in the treatment of alcobolism.
Rydzyński, Z., Cwynar, S., Grzelak, L., & Jagiello, W. (1968) · PubMed · Cited by 9
Research works printed but not linked: 1
- Albuquerque Fortes J. Psilocybin and chronic alcoholism. Arquivos Coordenadoria Saude Mental Estado Sao Paulo. (1966) 32: 5– 129.
Cited by
Sabé, M., Sulstarova, A., Glangetas, A., Pieri, M. D., Mallet, L., Curtis, L., Richard-Lepouriel, H., Penzenstadler, L. E., Seragnoli, F., Thorens, G., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02800-5 · Cited by 72
Mini-review: The neurobiology of treating substance use disorders with classical psychedelics
Urban, M. M., Stingl, M., & Meinhardt, M. W. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1156319 · Cited by 46
Fentanyl and Other Opioid Use Disorders: Treatment and Research Needs
Volkow, N. D., & Blanco, C. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230273 · Cited by 44
Psychedelics for treatment resistant depression: are they game changers?
Kalfas, M., Taylor, R. H., Tsapekos, D., & Young, A. H. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2281582 · Cited by 40
“Although we did not have the scope to discuss further effects in the present paper, psychedelic therapy holds promise for other psychiatric conditions including PTSD [111], anorexia [134], addiction [135], borderline personality disorder [136] and bipolar depression.”
BackgroundHovmand, O. R., Poulsen, E. D., & Arnfred, S. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811231200019 · Cited by 33
“…new instruments have been designed to assess the acute subjective psyche-delic experience, and the treatment outcomes have been discussed in multiple systematic reviews and meta-analyses (Castro Santos and Gama Marques, 2021; Hovmand et al., 2023; Kisely et al., 2023; van der Meer et al., 2023).”
Background
Metadata
- Authors
- van der Meer, P. B., Fuentes, J. J., Kaptein, A. A., Schoones, J. W., de Waal, M. M., Goudriaan, A. E., Kramers, K., Schellekens, A., Somers, M., Bossong, M. G., & Batalla, A.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Leiden University Medical Center (NL)
- Radboud University Medical Center (NL)
- University Medical Center Utrecht (NL)
- ORCID
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2023-02-09
- Volume
- 14
- Pages
- 1134454-1134454
- ISSN
- 1664-0640 (ISSN-L)
- PMC
- PMC9947277
- OpenAlex
- W4319765908
- Cited by
- 127
- References
- 41
- Citations by year
- 2026: 20 · 2025: 44 · 2024: 51 · 2023: 12
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- Repositori digital de la UPF (Universitat Pompeu Fabra) (acceptedVersion, cc-by)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Health › Religion, Spirituality, and Psychology
- Keywords
- psilocybin, psychedelic therapy, substance use disorders, alcoholism, tobacco use disorder, smoking abstinence, alcohol abstinence, heavy drinking days, long-term follow-up, treatment efficacy, dose-response relationship, adverse effects, anxiety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
